Wed, Sep 17, 2014, 12:31 PM EDT - U.S. Markets close in 3 hrs 29 mins


% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

  • a65232389 a65232389 Mar 22, 2013 3:42 PM Flag

    No sale

    Hong Zhao's appointment finally brings some actual management to this company. But his appointment also means that there is no plan or intention to sell the company. (BTW, if Zhao handles all of China, what's Blobel's job?) So it's back to making money (for investors) the old fashioned way, slugging it out in the China pharmaceutical marketplace. And it's tough. At Zhao's former company, Simcere, revenue for 2012 increased by just 2.1% and operating income (not counting writedowns) decreased by 4.7%. Sales of its lead product, Bupin, dropped about 9% because of increased competition. Zadaxin sales for 2012 will probably be shown as flat at best after factoring out the channel stuffing. So let's not expect Zhao to work miracles with what he's got to work with.

7.13-0.06(-0.83%)12:30 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.